Table 3.

Association of asymmetric dimethylarginine level and mortality in overall cohort and with interaction with race

Asymmetric DimethylarginineUnadjusted HR (95% CI)Model 1a HR (95% CI)Model 2b HR (95% CI)
Total cohort
 Continuous1.22 (1.03 to 1.44)1.25 (1.04 to 1.49)1.22 (1.01 to 1.47)
 Quartile 1ReferenceReferenceReference
 Quartile 21.23 (0.73 to 2.08)1.24 (0.73 to 2.10)1.12 (0.66 to 1.93)
 Quartile 31.22 (0.73 to 2.04)1.19 (0.71 to 2.00)1.12 (0.67 to 1.90)
 Quartile 41.91 (1.15 to 3.17)1.97 (1.17 to 3.34)1.84 (1.08 to 3.12)
Interaction with race
 African Americanc0.65 (0.30 to 1.44)0.66 (0.31 to 1.40)0.57 (0.28 to 1.18)
 Non–African Americanc1.16 (0.98 to 1.38)1.30 (1.08 to 1.56)1.29 (1.06 to 1.57)
  • HR per 1 SD change in asymmetric dimethylarginine (0.15 µmol/L), except for quartile analysis. HR, hazard ratio.

  • a Model 1: adjusted for age and sex.

  • b Model 2: adjusted for age, sex, dialysis vintage, vascular access type, history of cardiovascular disease, history of congestive heart failure, and diabetes.

  • c Models include interaction term between African American race and asymmetric dimethylarginine.